Biomea Fusion To Start Early-Stage Leukemia Setting Trial With BMF-219

  • The FDA has signed off Biomea Fusion Inc's BMEA Investigational New Drug application to begin a Phase 1 trial of BMF-219, a selective irreversible menin inhibitor.
  • The trial will include adult patients with relapsed or refractory acute leukemia, including those with an MLL/KM2TA gene rearrangement or NPM1 mutation.
  • The trial will assess the safety, pharmacokinetics (PK), and pharmacodynamic (PD) profile in adult patients.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: BMEA shares were up 5.64% at $11.23 before the trading was halted during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapFDAMoversTrading IdeasGeneralBriefsleukemiaPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!